---
schema_version: "secwatch.filing_event.v1"
accession: "0001174947-22-001093"
form_type: "8-K"
ticker: "CNMD"
cik: "0000816956"
company_name: "CONMED Corp"
filed_at: "2022-10-26T23:59:59+00:00"
generated_at: "2026-06-23T01:02:46.774181+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CONMED Q3 sales $275.1M (+10.6% YoY); adjusted EPS $0.77 misses prior year; narrows 2022 guidance

## Summary
- Sales $275.1M +10.6% as reported, +12.1% constant currency; domestic +14.2%, international +6.2% as reported.
- GAAP diluted EPS $1.48 (vs $0.47 Q3 2021); adjusted diluted EPS $0.77 (vs $0.80) down 3.8%.
- Full-year 2022 revenue guidance narrowed to $1.1B-$1.115B; adjusted EPS guidance lowered to $3.21-$3.28 from $3.25-$3.45.
- Closed Biorez acquisition on Aug 9, 2022; integrates with recent In2Bones acquisition.
- Orthopedic Surgery sales $118.6M +12.2% as reported; General Surgery $156.5M +9.4%. Single-use +15.1%, capital -8.5%.

## SEC filing metadata
- accession: 0001174947-22-001093
- form_type: 8-K
- ticker: CNMD
- cik: 0000816956
- company_name: CONMED Corp
- filed_at: 2022-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/816956/000117494722001093/0001174947-22-001093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/816956/000117494722001093/form8k-28878_cnmd.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001174947-22-001093
- JSON: https://secwatch.observer/filing/0001174947-22-001093.json
- Plain text: https://secwatch.observer/filing/0001174947-22-001093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.